Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Selank and Epitalon — mechanism, side effects, legal status, and pricing.
Selank is a synthetic heptapeptide analog of the endogenous immunomodulatory tetrapeptide tuftsin, extended with a Pro-Gly-Pro C-terminus for metabolic stability. Developed at the Institute of Molecular Genetics (Russian Academy of Sciences), it is registered as an anxiolytic drug in Russia but is not approved by the FDA or EMA.
Epitalon (also Epithalon, AEDG) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology as a synthetic analog of the bovine pineal extract Epithalamin. It is a research-only bioregulator — not FDA-approved and not included in any major Western clinical guideline.
Selank
Epitalon
Category
Legal Status
Mechanism
Half-life
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Selank
Epitalon
COA corpus from Disclosed Labs — independently tested batches only.
Selank
81
COAs
99.6%
Avg purity
18
Labs
Epitalon
87
COAs
99.3%
Avg purity
14
Labs
Selank is among peptides under FDA review for the Category 1 (503A) list; if added, it would require a prescription to be compounded by registered 503A/503B pharmacies — not yet authorized. Epitalon remains research-only. In April 2026 the FDA removed 12 peptides from Category 2, which does not place them on the Category 1 list or authorize compounding. The FDA's Pharmacy Compounding Advisory Committee is advisory and meets July 23–24, 2026 to review nominations and make recommendations to the FDA.
Selank's clinical evidence base is almost entirely Russian. Zozulia et al. (2008, Zh Nevrol Psikhiatr Im S S Korsakova; PMID 18454096) compared selank to medazepam in 62 patients with generalized anxiety disorder and neurasthenia, reporting comparable anxiolytic efficacy plus antiasthenic/psychostimulant effects, together with changes in serum enkephalin-degrading enzyme activity. Mechanistic work includes Inozemtseva et al. (2008, Dokl Biol Sci; PMID 18841804) showing intranasal Selank increases hippocampal BDNF mRNA and protein in rats, Volkova et al. (2016, Front Pharmacol; PMID 26924987) demonstrating modulation of GABAergic gene expression, and Vyunova et al. (2018, Protein Pept Lett; PMID 30255741) proposing a positive allosteric GABA-A mechanism. No US or EU regulatory clinical trials have been conducted; safety data outside Russia is limited.
Key references
The evidence base is dominated by the Khavinson group. A 2003 paper in Bulletin of Experimental Biology and Medicine (Khavinson, Bondarev, Butyugov; PMID 12937682) reported telomerase activation and telomere elongation in cultured human fetal fibroblasts. Additional Khavinson-group papers and reviews (e.g. 'Peptides and Ageing,' PMID 12374906) describe melatonin-rhythm normalization and claimed geroprotective effects in elderly Russian patients treated with epithalamin or epitalon in open-label / small-cohort studies over 6–12 year follow-up. These clinical studies have significant methodological limitations (open-label design, single-center, limited controls) and have NOT been independently replicated in rigorous Western controlled trials. There are no Phase 2/3 trials, no FDA approval, and no inclusion in Western clinical guidelines. Grey-market dosing of 5–10 mg SubQ daily for 10–20 day cycles, 1–2 times per year, is not clinically validated for any endpoint.
Selank (Cognitive) and Epitalon (Cosmetic) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Key references
Disclosed Labs